PDAC Clinical Trials

69 recruitingLast updated: June 17, 2026

There are 69 actively recruiting pdac clinical trials across 18 countries. Studies span Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1, Phase 4. Top locations include Boston, Massachusetts, United States, Fairfax, Virginia, United States, New York, New York, United States. Updated daily from ClinicalTrials.gov.


PDAC Trials at a Glance

69 actively recruiting trials for pdac are listed on ClinicalTrialsFinder across 6 cities in 18 countries. The largest study group is Phase 1 with 34 trials, with the heaviest enrollment activity in Boston, Fairfax, and New York. Lead sponsors running pdac studies include Revolution Medicines, Inc., Beijing Biotech, and Azienda Ospedaliera Universitaria Integrata Verona.

Treatments under study

About PDAC Clinical Trials

Looking for clinical trials for PDAC? There are currently 14 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new PDAC trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about PDAC clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 69 trials

Recruiting
Phase 2Phase 3

A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma

Metastatic Pancreatic Ductal AdenocarcinomaPDAC
AbbVie900 enrolled11 locationsNCT07490301
Recruiting
Phase 3

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

Pancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Adenocarcinoma Metastatic+5 more
Revolution Medicines, Inc.670 enrolled3 locationsNCT07621718
Recruiting
Phase 2

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma (PDAC)G12D Mutated KRAS
Verastem, Inc.180 enrolled8 locationsNCT07644559
Recruiting
Phase 1

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

KRAS-mutant Non-small Cell Lung Cancer (NSCLC)KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)KRAS-mutant Colorectal Cancer (CRC)+1 more
Kestrel Therapeutics, Inc.145 enrolled8 locationsNCT07458347
Recruiting
Phase 3

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Pancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Adenocarcinoma Metastatic+5 more
Immuneering Corporation510 enrolled17 locationsNCT07562152
Recruiting
Phase 2

A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic Ductal Adenocarcinoma (PDAC)
BicycleTx Limited39 enrolled2 locationsNCT07450859
Recruiting
Phase 1

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

CancerAdvanced Solid TumorsNSCLC (Non-small Cell Lung Cancer)+2 more
Alterome Therapeutics, Inc.448 enrolled12 locationsNCT06835569
Recruiting
Phase 1

Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Triple Negative Breast Cancer(TNBC)Soft Tissue Sarcoma (STS)+4 more
Novartis Pharmaceuticals66 enrolled1 locationNCT07630961
Recruiting
Phase 1

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer (CRC)+4 more
Kura Oncology, Inc.300 enrolled38 locationsNCT06026410
Recruiting
Phase 1Phase 2

Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC

PDAC
Anocca AB96 enrolled10 locationsNCT07145450
Recruiting
Phase 2

Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

Pancreatic Ductal Adenocarcinoma (mPDAC)
University of California, San Diego43 enrolled1 locationNCT06790602
Recruiting
Phase 3

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic CancerPDACPDAC - Pancreatic Ductal Adenocarcinoma+2 more
Revolution Medicines, Inc.500 enrolled17 locationsNCT07252232
Recruiting
Phase 1

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid Tumors+1 more
Revolution Medicines, Inc.604 enrolled17 locationsNCT06040541
Recruiting
Phase 3

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Pancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Adenocarcinoma Metastatic+5 more
Revolution Medicines, Inc.900 enrolled5 locationsNCT07491445
Recruiting
Phase 1Phase 2

Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma

Pancreatic Ductal Adenocarcinoma (PDAC)Metastatic DiseaseUnresectable Locally Advanced
Beijing Biotech42 enrolled1 locationNCT07627711
Recruiting
Phase 1

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Non-small Cell Lung CancerNSCLCMetastatic Pancreatic Ductal Adenocarcinoma+11 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)665 enrolled17 locationsNCT06917079
Recruiting
Phase 1

AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

Colorectal, CancerHormone Receptor-Positive Breast CarcinomaGastric Adenocarcinoma+6 more
Avacta Life Sciences Ltd174 enrolled3 locationsNCT07454642
Recruiting
Phase 3

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic Ductal Adenocarcinoma (PDAC)
SOFIE200 enrolled14 locationsNCT07217717
Recruiting
Phase 1

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Pancreatic CancerNon-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)+7 more
Revolution Medicines, Inc.574 enrolled5 locationsNCT07349537
Recruiting
Early Phase 1

Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals

Pancreatic CancerPancreatic Ductal AdenocarcinomaPDAC+2 more
Dana-Farber Cancer Institute5,000 enrolled2 locationsNCT06122896